c-Src phosphorylation and activation of hexokinase promotes tumorigenesis and metastasis

It is well known that c-Src has important roles in tumorigenesis. However, it remains unclear whether c-Src contributes to metabolic reprogramming. Here we find that c-Src can interact with and phosphorylate hexokinases HK1 and HK2, the rate-limiting enzymes in glycolysis. Tyrosine phosphorylation d...

Full description

Saved in:
Bibliographic Details
Published inNature communications Vol. 8; no. 1; p. 13732
Main Authors Zhang, Jia, Wang, Suili, Jiang, Bin, Huang, Lihong, Ji, Zhiliang, Li, Xiaotong, Zhou, Huamin, Han, Aidong, Chen, Ai, Wu, Yanan, Ma, Huanhuan, Zhao, Wentao, Zhao, Qingwen, Xie, Changchuan, Sun, Xiaoyan, Zhou, Yanming, Huang, Huiying, Suleman, Muhammad, Lin, Furong, Zhou, Lin, Tian, Fang, Jin, Meijun, Cai, Yana, Zhang, Nan, Li, Qinxi
Format Journal Article
LanguageEnglish
Published England Nature Publishing Group 05.01.2017
Nature Portfolio
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:It is well known that c-Src has important roles in tumorigenesis. However, it remains unclear whether c-Src contributes to metabolic reprogramming. Here we find that c-Src can interact with and phosphorylate hexokinases HK1 and HK2, the rate-limiting enzymes in glycolysis. Tyrosine phosphorylation dramatically increases their catalytic activity and thus enhances glycolysis. Mechanistically, c-Src phosphorylation of HK1 at Tyr732 robustly decreases its K and increases its V by disrupting its dimer formation. Mutation in c-Src phosphorylation site of either HK1 or HK2 remarkably abrogates the stimulating effects of c-Src on glycolysis, cell proliferation, migration, invasion, tumorigenesis and metastasis. Due to its lower K for glucose, HK1 rather than HK2 is required for tumour cell survival when glucose is scarce. Importantly, HK1-Y732 phosphorylation level remarkably correlates with the incidence and metastasis of various clinical cancers and may serve as a marker to predict metastasis risk of primary cancers.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
These authors contributed equally to this work
ISSN:2041-1723
2041-1723
DOI:10.1038/ncomms13732